Roche announces Operational Excellence initiative
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced the launch of a Group-wide Operational Excellence initiative. In view of mounting pressures to curb healthcare costs - especially in the United States and Europe - together with recent developments in late-stage projects in the Roche pipeline, this initiative aims to adapt cost structures and accelerate productivity improvements Group-wide.
BBC Panorama: "A Risk Worth Taking?" Programme. GlaxoSmithKline Right of Reply Statement
- Details
- Category: GlaxoSmithKline
Patient safety is our first priority. We strongly refute any allegation that our actions have put patients at risk. We have carried out an extensive research programme, involving more than 50,000 patients to analyse the safety and benefits of Avandia.
Novartis and collaborators discover novel antimalarial drug candidate
- Details
- Category: Novartis
Novartis announced that scientists at the Novartis Institute for Tropical Diseases (NITD), in collaboration with researchers from the Genomics Institute of the Novartis Research Foundation (GNF), the Swiss Tropical and Public Health Institute and The Scripps Research Institute have discovered a novel compound that shows promise as a next generation treatment for drug resistant malaria.
Reports of narcolepsy in Europe following vaccination with Pandemrix™
- Details
- Category: GlaxoSmithKline
GSK initially became aware of possible cases of narcolepsy following vaccination with the adjuvanted H1N1 pandemic vaccine Pandemrix through adverse event reports received by the Swedish Medical Products Agency, and subsequently via media reports in Finland.
Merck's Cladribine Tablets for Multiple Sclerosis Approved in Australia
- Details
- Category: Merck Group
Merck KGaA announced today that the Australian Therapeutic Goods Administration (TGA) has approved Cladribine Tablets for the treatment of relapsing-remitting multiple sclerosis (MS). Cladribine Tablets will be registered in Australia under the trade name Movectro®.
European Commission Issues Positive Decision for Approval of Seroquel XR
- Details
- Category: AstraZeneca
AstraZeneca announced that the European Commission (EC) has issued a positive decision for the approval of once-daily SEROQUEL XR (quetiapine fumarate) Extended Release Tablets as an add-on treatment of major depressive episodes in patients with Major Depressive Disorder (MDD) who have had sub-optimal response to antidepressant monotherapy.
Pfizer to Acquire FoldRx Pharmaceuticals
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) and FoldRx Pharmaceuticals, Inc., a privately held drug discovery and clinical development company, have entered into an agreement under which Pfizer will acquire FoldRx. FoldRx's portfolio includes clinical and pre-clinical programs for investigational compounds to treat diseases caused by protein misfolding, which is increasingly recognized as an underlying cause in many chronic degenerative diseases.
More Pharma News ...
- Global market launch of Daxas® (Roflumilast) kicks off in Germany
- Bayer's Rivaroxaban Successfully Meets Primary Efficacy Outcome
- Shire Announces Support for Inflammatory Bowel Disease (IBD) Fellowships
- Genzyme Confirms Receipt of Unsolicited Proposal
- Sanofi-aventis Announces Non-Binding Offer to Acquire Genzyme
- Genetic substudy shows fewer major cardiovascular events with ticagrelor (BRILINTA)
- Boehringer Ingelheim inaugurates the Shanghai "Center of Competence"